X4 Pharmaceuticals (XFOR) Revenue (2018 - 2025)
X4 Pharmaceuticals posted quarterly Revenue of $2.6 million for Q4 2025, up 79.08% year-on-year from $1.4 million in Q4 2024, and up 45.5% on a QoQ basis from $1.8 million in Q3 2025.
X4 Pharmaceuticals (XFOR) has 4 years of Revenue data on file, last reported at $2.6 million in Q4 2025.
- For the quarter ending Q4 2025, Revenue rose 79.08% year-over-year to $2.6 million; the trailing twelve-month figure through Dec 2025 stood at $35.1 million (up 1273.21% YoY), and the FY2025 full-year result was $35.1 million, up 1273.21% from the prior year.
- Revenue for Q4 2025 stood at $2.6 million, up from $1.8 million in the prior quarter.
- Across five years, Revenue topped out at $28.8 million in Q1 2025 and bottomed at $560000.0 in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | X4 Pharmaceuticals | 182.28 Mn | 182.28 Mn | 2.20 Mn | 2.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.57 Mn |
| Sep 30, 2025 | 1.77 Mn |
| Jun 30, 2025 | 1.97 Mn |
| Mar 31, 2025 | 28.81 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Sep 30, 2024 | 560,000.00 |
| Jun 30, 2024 | 563,000.00 |
| Mar 31, 2020 | 3.00 Mn |
| Dec 31, 2018 | 3.50 Mn |